HuGE Literature Finder
Records
1
-
5
Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy. World journal of gastroenterology 2016 Aug 22 (30): 6944-54. Lo Nigro Cristiana, Ricci Vincenzo, Vivenza Daniela, Granetto Cristina, Fabozzi Teresa, Miraglio Emanuela, Merlano Marco |
The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis. Acta oncologica (Stockholm, Sweden) 2014 Jul 53 (7): 852-64. Therkildsen Christina, Bergmann Troels K, Henrichsen-Schnack Tine, Ladelund Steen, Nilbert M |
Phosphatidylinositol-3-kinase pathway aberrations in gastric and colorectal cancer: meta-analysis, co-occurrence and ethnic variation. International journal of cancer. Journal international du cancer 2014 Mar 134 (5): 1232-8. Chong Mei-Ling, Loh Marie, Thakkar Bhavin, Pang Brendan, Iacopetta Barry, Soong Rich |
Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis. International journal of cancer. Journal international du cancer 2013 Mar . Yang ZY, Wu XY, Huang YF, Di MY, Zheng DY, Chen JZ, Ding H, Mao C, Tang JL |
Loss of PTEN expression as a predictor of resistance to anti-EGFR monoclonal therapy in metastatic colorectal cancer: evidence from retrospective studies. Cancer chemotherapy and pharmacology 2012 Jun 69 (6): 1647-55. Wang Zhen-Hua, Gao Qin-Yan, Fang Jing-Yu |
- Page last reviewed:Jul 25, 2022
- Page last updated:Aug 03, 2022
- Content source: